Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
NASDAQ:ASND
Price:
135.9 USD
-0.75%
Market Closed
Updated:
Apr 28, 2024
Ascendis Pharma A/S
Cash from Financing Activities
|
Ascendis Pharma A/S
Cash from Financing Activities Peer Comparison
Comparables:
GMAB
ZEAL
B
BAVA
BIOPOR
SANION
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Financing Activities
€134.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Financing Activities
-kr606m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Financing Activities
kr907m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Financing Activities
kr735.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Financing Activities
kr40.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Saniona AB
STO:SANION
|
Cash from Financing Activities
-kr8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Ascendis Pharma A/S's Cash from Financing Activities?
Cash from Financing Activities
134.3m
EUR
134.3m
EUR
Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Cash from Financing Activities amounts to 134.3m EUR.
What is Ascendis Pharma A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-8%
-8%
Over the last year, the Cash from Financing Activities growth was -66%. The average annual Cash from Financing Activities growth rates for Ascendis Pharma A/S have been -39% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
